Avis Budget Group (CAR) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates…

ORLANDO, Fla.--(BUSINESS WIRE)--A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with difficult-to-treat lupus, according to a new study from research…

Avis Budget Group experienced a dramatic short squeeze, surging from $100 to $800 before collapsing as institutional holders exited. Pentwater Capital's exit and subsequent $650 million settlement with Avis ended the squ…

CAR shares jump 10.2% despite a Q3 earnings miss, as record fleet utilization, improved cash flow and expectations of Q4 EBITDA recovery draw attention.…

Lyell Immunopharma NASDAQ: LYEL expects pivotal data in mid-2027 for its lead CAR-T cell therapy, ronde-cel, as the company advances the treatment in patients with large B-cell lymphoma who have received at least two pri…

Avis Budget Group, Inc. ( CAR ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants David Calabria - Treasurer & Senior VP of Corporate Finance Brian Choi - Chief Executive Officer Daniel Cunha - Exec…

Avis Budget Group NASDAQ: CAR reported third-quarter adjusted EBITDA of $513 million, down 8% from a year earlier and about $50 million below the company's prior expectations, as weaker travel demand in August pressured …

Dr. Robert Wenham, principal investigator of Anixa's Phase 1 clinical trial at Moffitt Cancer Center, to present on December 14 in London SAN JOSE, Calif., Nov. 4, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or…

The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the yea…

Avis Budget Group (CAR) came out with quarterly earnings of $5.15 per share, missing the Zacks Consensus Estimate of $8.47 per share. This compares to earnings of $10.11 per share a year ago.…

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

Hennessy Advisors Inc. decreased its stake in shares of Avis Budget Group, Inc. (NASDAQ: CAR) by 8.9% in a recent quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,30…

Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in AChR Ab+ Myasthenia Gra…

Avis Budget (CAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

PARSIPPANY, N.J.--(BUSINESS WIRE)--Avis announced the expansion of Avis First to London Heathrow and Paris Charles de Gaulle airports, bringing its premium car rental service to more than 30 airport and city locations ac…

First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities observed to date Patients i…

On October 21, 2026, Avis Budget Group Inc (CAR) shares fell 4.0%, bringing the current price to $98.39. This price is down significantly from its 52-week high…

CAR, USAS and APC have been added to the Zacks Rank #5 (Strong Sell) List on October 20, 2026.…

First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial efficacy data expec…

LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T thera…

Previously announced wind-down of the legacy cell therapy activities is substantially complete Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that…

Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a bi…

Beaten-down rental stocks are bouncing while the wider transportation sector slips, and Hertz Global Holdings (NASDAQ:HTZ) is leading the rebound from the deepest hole in the group. Hertz stock is at $2.…

First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities obser…
No recent releases where the company itself is speaking.
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

